|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Antoon JW, Lai R, Struckhoff AP, et al:
Altered death receptor signaling promotes epithelial-to-mesenchymal
transition and acquired chemoresistance. Sci Rep. 2:5392012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
White NJ: Qinghaosu (artemisinin): the
price of success. Science. 320:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
German PI and Aweeka FT: Clinical
pharmacology of artemisinin-based combination therapies. Clin
Pharmacokinet. 47:91–102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Efferth T: Willmar Schwabe Award 2006:
antiplasmodial and antitumor activity of artemisinin - from bench
to bedside. Planta Med. 73:299–309. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Efferth T, Dunstan H, Sauerbrey A, Miyachi
H and Chitambar CR: The anti-malarial artesunate is also active
against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI
|
|
7
|
Klayman DL: Qinghaosu (artemisinin): an
antimalarial drug from China. Science. 228:1049–1055. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Disbrow GL, Baege AC, Kierpiec KA, et al:
Dihydroartemisinin is cytotoxic to papillomavirus-expressing
epithelial cells in vitro and in vivo. Cancer Res. 65:10854–10861.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hosoya K, Murahari S, Laio A, London CA,
Couto CG and Kisseberth WC: Biological activity of
dihydroartemisinin in canine osteosarcoma cell lines. Am J Vet Res.
69:519–526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mercer AE, Copple IM, Maggs JL, O’Neill PM
and Park BK: The role of heme and the mitochondrion in the chemical
and molecular mechanisms of mammalian cell death induced by the
artemisinin antimalarials. J Biol Chem. 286:987–996. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang S and Gerhard GS: Heme mediates
cytotoxicity from artemisinin and serves as a general
anti-proliferation target. PLoS One. 4:e74722009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toovey S, Bustamante LY, Uhlemann AC, East
JM and Krishna S: Effect of artemisinins and amino alcohol partner
antimalarials on mammalian sarcoendoplasmic reticulum calcium
adenosine triphosphatase activity. Basic Clin Pharmacol Toxicol.
103:209–213. 2008. View Article : Google Scholar
|
|
13
|
Handrick R, Ontikatze T, Bauer KD, et al:
Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic
pathway. Mol Cancer Ther. 9:2497–2510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eckstein-Ludwig U, Webb RJ, Van Goethem
ID, et al: Artemisinins target the SERCA of Plasmodium
falciparum. Nature. 424:957–961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen T, Li M, Zhang R and Wang H:
Dihydroartemisinin induces apoptosis and sensitizes human ovarian
cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang SJ, Gao Y, Chen H, et al:
Dihydroartemisinin inactivates NF-kappaB and potentiates the
anti-tumor effect of gemcitabine on pancreatic cancer both in vitro
and in vivo. Cancer Lett. 293:99–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen M, Chen TS, Lu YY, Liu CY and Qu JL:
Dihydroarteminsinin-induced apoptosis is not dependent on the
translocation of Bim to the endoplasmic reticulum in human lung
adenocarcinoma cells. Pathol Oncol Res. 18:809–816. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Q, Shi J, Shen XL, et al:
Dihydroartemisinin upregulates death receptor 5 expression and
cooperates with TRAIL to induce apoptosis in human prostate cancer
cells. Cancer Biol Ther. 9:819–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singh NP and Lai H: Selective toxicity of
dihydroartemisinin and holotransferrin toward human breast cancer
cells. Life Sci. 70:49–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh NP and Lai HC: Synergistic
cytotoxicity of artemisinin and sodium butyrate on human cancer
cells. Anticancer Res. 25:4325–4331. 2005.PubMed/NCBI
|
|
21
|
Zhang CZ, Zhang H, Yun J, Chen GG and Lai
PB: Dihydroartemisinin exhibits antitumor activity toward
hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol.
83:1278–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang XJ, Ma ZQ, Zhang WP, Lu YB and Wei
EQ: Dihydroartemisinin exerts cytotoxic effects and inhibits
hypoxia inducible factor-1alpha activation in C6 glioma cells. J
Pharm Pharmacol. 59:849–856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mercer AE, Maggs JL, Sun XM, et al:
Evidence for the involvement of carbon-centered radicals in the
induction of apoptotic cell death by artemisinin compounds. J Biol
Chem. 282:9372–9382. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao N, Budhraja A, Cheng S, et al:
Interruption of the MEK/ERK signaling cascade promotes
dihydroartemisinin-induced apoptosis in vitro and in vivo.
Apoptosis. 16:511–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reungpatthanaphong P and Mankhetkorn S:
Modulation of multidrug resistance by artemisinin, artesunate and
dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines.
Biol Pharm Bull. 25:1555–1561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan J, Murrell GA, Trickett A and Wang
MX: Involvement of cytochrome c release and caspase-3 activation in
the oxidative stress-induced apoptosis in human tendon fibroblasts.
Biochim Biophys Acta. 1641:35–41. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Noori S and Hassan ZM: Dihydroartemisinin
shift the immune response towards Th1, inhibit the tumor growth in
vitro and in vivo. Cell Immunol. 271:67–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aung W, Sogawa C, Furukawa T and Saga T:
Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor
model evaluated by conventional methods and optical imaging.
Anticancer Res. 31:1549–1558. 2011.PubMed/NCBI
|
|
29
|
Kelman Z: PCNA: structure, functions and
interactions. Oncogene. 14:629–640. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu JJ, Chen SM, Ding J and Meng LH:
Characterization of dihydroartemisinin-resistant colon carcinoma
HCT116/R cell line. Mol Cell Biochem. 360:329–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morrissey C, Gallis B, Solazzi JW, et al:
Effect of artemisinin derivatives on apoptosis and cell cycle in
prostate cancer cells. Anticancer Drugs. 21:423–432. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Renz A, Berdel WE, Kreuter M, Belka C,
Schulze-Osthoff K and Los M: Rapid extracellular release of
cytochrome c is specific for apoptosis and marks cell death in
vivo. Blood. 98:1542–1548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bouillet P, Purton JF, Godfrey DI, et al:
BH3-only Bcl-2 family member Bim is required for apoptosis of
autoreactive thymocytes. Nature. 415:922–926. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L, He F, Liu H, et al: Natural
diterpenoid compound elevates expression of Bim protein, which
interacts with antiapoptotic protein Bcl-2, converting it to
proapoptotic Bax-like molecule. J Biol Chem. 287:1054–1065. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wojciechowski S, Tripathi P, Bourdeau T,
et al: Bim/Bcl-2 balance is critical for maintaining naive and
memory T cell homeostasis. J Exp Med. 204:1665–1675.
2007.PubMed/NCBI
|
|
37
|
Willis SN, Fletcher JI, Kaufmann T, et al:
Apoptosis initiated when BH3 ligands engage multiple Bcl-2
homologs, not Bax or Bak. Science. 315:856–859. 2007. View Article : Google Scholar : PubMed/NCBI
|
